Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Fig. 6

Adverse events of special interest per 100 patient-years during the overall period: a serious infections, b herpes zoster-related disease, c malignancies (SAF). Patient-years was calculated from initial dose up to first incidence of the event for patients who had at least one event, and from initial dose through follow up for patients who had no events; IR was calculated as (100 × number of patients with ≥ 1 incidence/total patient-years) CI confidence interval, IR incidence rate

Back to article page
\